Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21312707 | 0.96 | RHEB (0.39) | RHEBMEN1HTTKMT2AHAO1 | |
| SCHEMBL21312823 | 0.85 | ALDH1A1 (0.37) | MEN1HTTKMT2AHAO1ALDH1A1 | |
| SCHEMBL23319917 | 0.84 | RHEB (0.40) | RHEBMEN1KMT2AHAO1 | |
| SCHEMBL21296965 | 0.84 | SMN1; SMN2 (0.41) | HAO1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21296958 | 0.84 | HAO1 (0.54) | RHEBMEN1KMT2AHAO1 | |
| SCHEMBL21312821 | 0.84 | HAO1 (0.37) | MEN1KMT2AHAO1ALDH1A1HPGD | |
| SCHEMBL21296860 | 0.83 | KDM4E (0.38) | MEN1KMT2AHAO1HPGDLMNA | |
| SCHEMBL23001914 | 0.82 | KMT2A (0.37) | RHEBMEN1KMT2AHAO1ALDH1A1 | |
| SCHEMBL21296911 | 0.81 | SRD5A2 (0.41) | HAO1 | |
| SCHEMBL21312822 | 0.81 | MAOA (0.44) | HTTHAO1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | PHOENIX TISSUE REPAIR, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20210403439-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | VENTHERA, INC. | 2021-12-30 | — | — | US | disclosed |
| EP-3817816-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | Orfan Biotech Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112399873-A | Triazole glycolate oxidase inhibitor | 奥凡生物科技公司 | 2021-02-23 | — | — | CN | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143491-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | RHEB 3863/4885MEN1 3362/4885HTT 4396/4885 |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | RHEB 2585/4885MEN1 3426/4885HTT 2347/4885 |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, LOX | RHEB 2585/4885MEN1 3426/4885HTT 2347/4885 |
| US-20210403439-A1 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | XDH, DUOX1, PNPO | RHEB 3863/4885MEN1 3362/4885HTT 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.